130 related articles for article (PubMed ID: 7353371)
1. The effect of 1,25 (OH)2D3 on bone mineralization: ultrastructural studies in patients with renal osteodystrophy.
Krempien B; Ritz E; Tschöpe W
Contrib Nephrol; 1980; 18():122-34. PubMed ID: 7353371
[TBL] [Abstract][Full Text] [Related]
2. The action of 1,25 (OH)2D3 on turnover kinetic, remodelling surfaces and structure of trabecular bone in chronic renal failure.
Delling G; Lühmann H; Bulla M; Fuchs C; Henning HV; Jansen JL; Kohnle W; Schulz W
Contrib Nephrol; 1980; 18():105-21. PubMed ID: 7353369
[TBL] [Abstract][Full Text] [Related]
3. The effect of hemodialysis, vitamin D metabolites and renal transplantation on the skeletal demineralization associated with renal osteodystrophy: a computerized histomorphometric analysis.
Main J; Velasco N; Catto GR; Fraser RA; Edward N; Adami S; O'Riordan JL
Clin Nephrol; 1986 Dec; 26(6):279-87. PubMed ID: 3542321
[TBL] [Abstract][Full Text] [Related]
4. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
[TBL] [Abstract][Full Text] [Related]
5. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
Massry SG; Goldstein DA; Malluche HH
Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
[No Abstract] [Full Text] [Related]
6. 1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy.
Pierides AM; Ellis HA; Dellagrammatikas H; Scott JE; Norman AW
Arch Dis Child; 1977 Jun; 52(6):464-72. PubMed ID: 879832
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S
Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529
[TBL] [Abstract][Full Text] [Related]
8. Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
Baker LR; Muir JW; Cattell WR; Tucker KA; Sharman VL; Goodwin FJ; Marsh FP; Hately W; Morgan AG; de Saintonge DM
Contrib Nephrol; 1980; 18():147-51. PubMed ID: 7353373
[TBL] [Abstract][Full Text] [Related]
9. Bone modelling processes at the endosteal surface of human femora. Scanning electron microscopical studies in normal bone and in renal osteodystrophy.
Krempien B
Virchows Arch A Pathol Anat Histol; 1979 May; 382(1):73-88. PubMed ID: 157599
[TBL] [Abstract][Full Text] [Related]
10. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
[TBL] [Abstract][Full Text] [Related]
11. Can bone histomorphometry be predicted by clinical assessment and noninvasive techniques in peritoneal dialysis?
Joffe P; Heaf JG; Jensen C
Miner Electrolyte Metab; 1996; 22(4):224-33. PubMed ID: 8807626
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy of uremic osteodystrophy in adults with calcitriol.
Moorthy AV; Harrington AR; Mazess RB; Simpson DP
Clin Nephrol; 1981 Aug; 16(2):93-100. PubMed ID: 6894893
[TBL] [Abstract][Full Text] [Related]
13. Decreased renal function in association with administration of 1,25-dihydroxyvitamin D3 to patients with stable, advanced renal failure.
Christiansen C; Røodbro P; Christensen MS; Naestoft J; Hartnack B; Transbøol I
Contrib Nephrol; 1980; 18():139-46. PubMed ID: 6243527
[TBL] [Abstract][Full Text] [Related]
14. [A pathological analysis of 51 cases of renal osteodystrophy].
Yu YF; Hu YX; Zhu P
Zhonghua Nei Ke Za Zhi; 1993 Jul; 32(7):448-50. PubMed ID: 8275821
[TBL] [Abstract][Full Text] [Related]
15. Randomized double blind study of 1, 25(OH)2D3 in dialysis patients.
Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC; Kleit SA
Proc Clin Dial Transplant Forum; 1977; 7():166-9. PubMed ID: 210446
[No Abstract] [Full Text] [Related]
16. Iliac bone marrow mast cells in relation to the renal osteodystrophy of patients treated by haemodialysis.
Ellis HA; Peart KM
J Clin Pathol; 1976 Jun; 29(6):502-16. PubMed ID: 939806
[TBL] [Abstract][Full Text] [Related]
17. Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy.
Fukushima M; Niki R; Ohkawa H; Shimizu T; Matsunaga I; Nakano H; Takagaki Y; Nishii Y; Okano K; Suda T
Endocrinology; 1980 Jul; 107(1):328-33. PubMed ID: 6247140
[TBL] [Abstract][Full Text] [Related]
18. [Renal osteodystrophy in children. Therapy with 1,25-dihydroxy-cholechalciferol (author's transl)].
Bulla M; Delling G; Benz-Bohm G; Stock GJ; Sánchez de Reutter A; Ziegler R; Lühmann H; Severin M; Kalbitzer E; Manegold C
Klin Wochenschr; 1980 May; 58(10):511-9. PubMed ID: 7392529
[TBL] [Abstract][Full Text] [Related]
19. Morphological effects of vitamin D and its analogs on bone.
Teitelbaum SL
Am J Clin Nutr; 1976 Nov; 29(11):1300-6. PubMed ID: 998541
[TBL] [Abstract][Full Text] [Related]
20. Interactions between treatment with 1,25(OH)2D3 and glucocorticoids in uremic patients after kidney transplantation.
Wong EG; Siemsen AW; Sugihara JG; Coburn JW
Contrib Nephrol; 1980; 18():152-61. PubMed ID: 6986228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
